Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole
-
- M. Biagi
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- X. Tan
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- T. Wu
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- M. Jurkovic
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- A. Vialichka
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- K. Meyer
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- R. E. Mendes
- JMI Laboratories, North Liberty, Iowa, USA
-
- E. Wenzler
- College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
-
- Nathan A. Ledeboer
- editor
抄録
<jats:p> <jats:named-content content-type="genus-species">Stenotrophomonas maltophilia</jats:named-content> is difficult to treat due to the production of multiple intrinsic and acquired mechanisms of resistance. Trimethoprim-sulfamethoxazole (TMP-SMZ) and the fluoroquinolones have traditionally been considered the drugs of choice but are plagued by increasing resistance and adverse drug effects. The objective of this study was to evaluate the <jats:italic>in vitro</jats:italic> activities of 12 clinically relevant antimicrobials against clinical <jats:named-content content-type="genus-species">S. maltophilia</jats:named-content> isolates nonsusceptible to levofloxacin and/or TMP-SMZ. </jats:p>
収録刊行物
-
- Journal of Clinical Microbiology
-
Journal of Clinical Microbiology 58 (2), 2020-01-28
American Society for Microbiology